Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 19, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - October 19, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/18/17 - AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA?/VENCLYXTO? (Venetoclax) Tablets in Combination with Rituxan (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
AbbVie, a global research and development-based biopharmaceutical company, today announced that the Phase 3 MURANO study of VENCLEXTA?/ VENCLYXTO? Tablets in combination with Rituxan met its primary endpoint. Doctors will continue to monitor patients who remain active in the MURANO trial in efforts to obtain additional, longer-term safety
9/18/17 - Crescita Therapeutics Reports Positive Topline Results of Phase 2 Clinical Trial for the Treatment of Plaque Psoriasis
-Crescita Therapeutics Inc., a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products today announced that it has received positive topline results from a Phase 2 clinical trial in patients with plaque psoriasis conducted by its partner, Ferndale Laboratories, Inc., in conjuncti
9/18/17 - Crescita Therapeutics? Reports Positive Topline Results of Phase 2 Clinical Trial for the Treatment of Plaque Psoriasis
-Crescita Therapeutics Inc., a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products today announced that it has received positive topline results from a Phase 2 clinical trial in patients with plaque psoriasis conducted by its partner, Ferndale Laboratories, Inc., in conjuncti
9/18/17 - OTC Markets Group Welcomes New OTCQB Companies
Release date- 15092017- New York, NY- OTC Markets Group Inc., operator of financial markets for 10,000 U.S. and global securities, today announced the following companies are approved for trading on the OTCQB Venture Market. Delcath Systems, Inc. Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology.
9/18/17 - Patent Application Titled "Pharmaceutical and Biological Agent Delivery System Having Biometric Data Acquisition and Monitoring Capabilities"...
Patent Application Titled "Pharmaceutical and Biological Agent Delivery System Having Biometric Data Acquisition and Monitoring Capabilities" Published Online. By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventors Hag
9/18/17 - Perrigo Announces Tentative FDA Approval For The Generic Version Of Acanya Gel
Perrigo Company plc today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya topical gel 1.2%/ 2.5%. Perrigo previously settled litigation with Dow Pharmaceutical Sciences, Inc. and Valeant Pharmaceuticals North America LLC for this product. Perrigo Company plc, a leading g
9/18/17 - Researchers Submit Patent Application, "Solid Pharmaceutical Agent Dosage Form Dispensing and Biometric Data Acquisition Device", for Approval (USPTO...
Researchers Submit Patent Application, "Solid Pharmaceutical Agent Dosage Form Dispensing and Biometric Data Acquisition Device", for Approval. By a News Reporter-Staff News Editor at Pharma Business Week From Washington, D.C., NewsRx journalists report that a patent application by the inventors Hagen, Tony A.; Hagen, Tim; Zastrow, Jake, filed on
9/16/17 - New Two-Year TREMFYA? (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance
Janssen Research& Development, LLC presented today new longer-term data from the open-label extension of the VOYAGE 1 trial demonstrating consistent rates of skin clearance with TREMFYA? treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin -23 monoclonal...
9/16/17 - Pharmacists play an important role in monitoring, policy making and regulatory affairs - Latif Sheikh
Abdul Latif Sheikh a well known pharmacist and President of Pakistan Health System Pharmacists while highlighting the role of pharmacists in creating health awareness at the Pakistan Pharma Summit-III organized by PPMA at Lahore from July 23-25, 2017. Total Pakistan Pharmaceutical market, he said, was over two Billion US$. Having looked at the webs
9/16/17 - Regeneron and Sanofi Announce Positive Study Results for DUPIXENT (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
TARRYTOWN, N.Y. and PARIS, Sept. 16, 2017/ PRNewswire/ Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the Phase 3 CAF? study of DUPIXENT in adults with moderate-to-severe atopic dermatitis who are inadequately controlled with or are intolerant to the broad immunosuppressant drug cyclosporine A, or when this t
9/15/17 - Advisory Committee; Nonprescription Drugs Advisory Committee, Renewal
SUMMARY: The Food and Drug Administration is announcing the renewal of the Nonprescription Drugs Advisory Committee by the Commissioner of Food and Drugs. SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by the Department of Health and Human Services pursuant to 45 CFR part 11 and by the General Services Administration, FDA is an
9/15/17 - BioPharmX Reports Second Quarter 2018 Financial Results
Release date- 14092017- MENLO PARK, Calif.- BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, today announced its financial results for the second quarter ended July 31, 2017 and discussed the progress of its clinical research. 'Momentum that began during our first quarter continues,' said BioPharmX President Anja K
9/15/17 - Neos Therapeutics Receives U.S. FDA Approval ofAdzenys ER? (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older
Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products using its proprietary modified-release drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved Adzenys ER? Extended-Release Oral Suspension.
9/15/17 - Pharmacists play an important role in monitoring, policy making and regulatory affairs - Latif Sheikh
Abdul Latif Sheikh a well known pharmacist and President of Pakistan Health System Pharmacists while highlighting the role of pharmacists in creating health awareness at the Pakistan Pharma Summit-III organized by PPMA at Lahore from July 23-25, 2017. Total Pakistan Pharmaceutical market, he said, was over two Billion US$. Having looked at the webs
9/15/17 - Valeant Commits $200,000 to Support Hurricane Relief Efforts
Valeant Pharmaceuticals International, Inc. today announced the Company and its employees through a matching donation program will donate $200,000 to the American Red Cross to support its efforts in the areas affected by Hurricanes Harvey and Irma. Additionally, Valeant has worked with Americares to donate more than $2 million of critically neede
9/15/17 - With a Healthy 6.9% CAGR, Veterinary Vaccines Market Is Expected to Rise US $11.40 Bn by the End of 2024
Transparency Market Research Report Added "Veterinary Vaccines Market" to its database.Albany, NY 09/15/2017 Live Attenuated Vaccines to Make Sizeable Contribution to Overall Revenues The global market for veterinary vaccines is expected to expand at a healthy 6.9% CAGR over the period between 2016 and 2024. The market, which had a valuation
9/14/17 - BioPharmX Announces Preliminary Data from Rosacea Feasibility Study
Release date- 13092017- MENLO PARK, Calif.- BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, is announcing preliminary data from a feasibility study of BPX-01 to assess the safety and efficacy of topical minocycline gel at both the 1% and 2% doses for the treatment of rosacea. The preliminary data from the ongoing
9/14/17 - House Conducted 11 Committee Hearings Yesterday
The U.S. House of Representatives conducted 11 committee hearings yesterday:. "Modernizing FDA's Regulation of Over-the-Counter Drugs". Testimony was heard from Janet Woodcock, Director, Center for Drug Evaluation and Research, Food and Drug Administration; and public witnesses.
9/14/17 - Innovus Pharma to Present at Rodman & Renshaw 19th Annual Global Investment Conference
By a News Reporter-Staff News Editor at Women's Health Weekly Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, announced that Dr. The corporate...
9/14/17 - Sunovion's Aptiom (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older
Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration approved the supplemental New Drug Application to expand the indication for its antiepileptic drug Aptiom to include treatment of partial-onset seizures in children and adolescents four to 17 years of age. APTIOM is also approved in the U.S. for the treatmen
9/13/17 - "Modernizing FDA's Regulation of Over-the-Counter Drugs."
FDA regulates most of the drugs on drug store shelves under the "OTC monograph system," though manufacturers do have the option to file a new drug application in lieu of using the OTC monograph system for OTC products. FDA publishes monographs that provide a rulebook for marketing safe and effective products containing particular active ingredients
9/13/17 - BioPharmX Reports Second Quarter 2018 Financial Results
BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, today announced its financial results for the second quarter ended July 31, 2017 and discussed the progress of its clinical research. "Momentum that began during our first quarter continues," said BioPharmX President Anja Krammer. During the past month, BioPharmX
9/13/17 - HEALTHCARE - Ascendis has Europe acquisitions in sights
Ascendis Health is eyeing bolt-on acquisitions in Central and Eastern Europe in 2018 to boost its business. The healthcare group bought a number of companies in countries such as Cyprus that lifted its revenue for the year to June. The company had acquired pharmaceutical manufacturer Remedica Holdings in Cyprus and European sports nutrition busines
9/13/17 - House Schedules 11 Committee Hearings for Sept. 13
The U.S. House of Representatives scheduled 11 committee hearings for Sept. 13:. Subcommittee on Workforce Protections; and Subcommittee on Health, Employment, Labor, and Pensions:. "Modernizing FDA's Regulation of Over-the-Counter Drugs".
9/13/17 - PLx Pharma Retains Dr. Efthymios N. Deliargyris as Chief Medical Advisor
PLx Pharma Inc., a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec? 325 mg and Aspertec? 81 mg, today announced the addition of Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI, as Chief Medical Advisor. Deliargyris, an internationally-recognized expert in the field of thrombosis,
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415